Heterotopic ossification (HO) is bone formation that occurs after trauma within tissues that do not normally have the property of ossification, resulting in pain and disability.
INTRODUCTION
Heterotopic ossification (HO) is the pathological formation of bone within extraskeletal tissues that do not normally ossify. HO is a common sequel of trauma, developing in approximately two thirds of casualties after blast injury. 1, 2 It is also common after hip replacement surgery (total hip arthroplasty, THA) with a reported incidence between 5% for more severe disease and up to 90% for milder forms. 3, 4 HO also occurs after traumatic brain injury and burns. 5, 6 The clinical impacts of HO include pain and restricted movement, and symptoms due to the compression of adjacent structures, such as nerves and blood vessels. Clinical risk factors for HO after THA include male sex, hypertrophic osteoarthritis, ankylosing spondylitis, hip ankylosis, and African-American ethnicity that suggest a common, complex aetiology. 7, 8 Currently, there are no effective, mechanism-based treatments for HO, and thus identification of focussed, actionable drug targets is required.
Fibrodysplasia ossificans progressiva (FOP) is a rare but devastating and invariably fatal monogenic disease that is also characterised by bone formation at extraskeletal sites. In 97% of cases it is caused by a constitutively-activating mutation in the Activin receptor A type I gene (ACVR1) that codes for a type I bone morphogenetic protein (BMP) receptor. 9, 10 In contrast, the molecular pathogenesis of common, complex HO is poorly understood, although BMP-induced signalling is also thought to play a role. 11, 12 BMPs are members of the transforming growth factor beta (TGF-ß) superfamily and signal via type 1 and type 2 BMP cell surface receptors. [13] [14] [15] BMP2 is overexpressed in clinically evolving HO tissue after trauma, 16, 17 and BMP type 1 or 2 receptor inhibition reduces HO formation in experimental models. 18, 19 This pathway plays a central role in bone regeneration and repair, inducing the proliferation and differentiation of condensing mesenchymal stem cells (MSCs) towards chondrocytes and osteoblasts. These signals are transduced via mitogen-activated protein kinase (MAPK) signalling 20 and/or SMAD complexes. 21 The canonical Wnt/ß-catenin pathway is also implicated in chondrocyte maturation and osteoblast differentiation. 22, 23 Both the BMP and Wnt pathways converge on the transcription factors Runx2 and Sp7 (Osterix), resulting in HO formation through either endochondral or intramembranous routes, 22, 24, 25 depending upon the local tissue environment.
Here, we report the first genome-wide association analyses for HO susceptibility and severity in patients after THA. Prioritised signals were followed up in an independent patient cohort. Expression of implicated genes was confirmed in human bone and mechanistically explored using in vitro models of osseous transdifferentiation. We found that variation in the long non-coding RNA-encoding gene CASC20 is robustly associated with HO susceptibility. We also found a putative association between variation within KIF26B, a kinesin gene, and the severity of HO development. However, we identified no association signals at or around the ACVR1 locus. We found that both CASC20 and KIF26B are expressed in human bone, and that both are induced in BMP2-stimulated primary human MSCs, resulting in osseous differentiation. In a murine model of osseous trans-differentiation we found that knockout of Kif26b abrogates BMP2-induced bone formation, Runx2 and Osterix expression and synthesis of bone matrix proteins. These effects were associated with dysregulated ERK1/2 MAP-kinase signalling. The identification of susceptibility loci and putative mechanisms in common, complex HO provide a novel opportunity for the development of targeted interventions.
RESULTS

Variation within the CASC20 locus is associated with HO susceptibility.
To examine the genetic architecture of HO, we conducted genome-wide association analyses for disease susceptibility (cases and controls) and disease severity (within cases) in patients not less than 1 year after total hip replacement for osteoarthritis.
Genome wide analysis of the discovery cohort identified an excess of signals associated with HO susceptibility (Figure 1A & 1B, and Supplementary Table 1 ). Following linkage disequilibrium (LD) pruning using the clumping function in PLINK 26 , we identified 20 independent signals at p < 2.68x10 -5 (Supplementary Table 2 ), thirteen of which passed our variant-level quality control (QC) pipeline for de novo replication (see Methods).
The strongest signal, which reached genome wide significance, lay in an intergenic region just downstream of ARHGAP18 that encodes a protein involved in the modulation of cell signalling, cell shape and motility. 27 p=9.39x10 -8 ; Supplementary Figure 1 ). CASC20 is a human only LNC RNA that has no orthologues in species outside apes. Both its mechanism of action and functional importance in health and disease are currently unexplored. Another strong signal, approaching genome wide significance (rs10882328, EA A, MAF 0.29, OR 0.58 [0.47-0.71], p=3.87x10 -7 ; Supplementary Figure 2 ) lay within LGI1 that encodes the Leucinerich, glioma inactivated 1 protein, and is expressed in neural tissue. 28 At replication in an independent THA patient cohort, four of the thirteen independent HO susceptibility signals that passed variant-level QC (Supplementary Figure 2B ). CASC20 resides in close proximity to BMP2 on chr20.
In order to confirm the origin of the signal as lying within CASC20 rather than BMP2, we increased the physical distance threshold used for clumping to 2000 kb either side of rs11699612 to include the whole BMP2 locus and most of the proximal coding genes.
We found no HO-associating variants within BMP2 nor any BMP2 variants in higher LD than r 2 =0.05 with the CASC20 variant, confirming CASC20 as the origin of the signal ( Supplementary Table 4 ). Given the proximity of CASC20 to BMP2, we further examined whether rs11699612 is a cis-acting expression quantitative trait locus (cis-eQTL) for BMP2 expression using RNA sequencing data from unstimulated primary chondrocytes and synoviocytes taken from an independent cohort of 100 patients undergoing joint replacement (See data availability section and bioRxiv manuscript biorxiv.org/content/10.1101/835850v1). Data were analysed using a GTEx modified version of FastQTL, 29 (PMID: 26708335) and confirmed no evidence of rs11699612 action as a cis-eQTL on BMP2 in chondrocytes, nor evidence of any other cis-acting eQTLs in BMP2 (Supplementary Table 5 ).
Variation within KIF26B and disease severity. Twenty-two signals were suggestively associated with HO severity, with clumped index variants at P<2.68x10 -5 , the most significant 10 of which were prioritised for replication ( Supplementary   Tables 6 and 7 ). The strongest signal lay within an intronic region of KIF26B (rs35338958, EA T, EAF 0.10, OR 3.04 [1.85-5.01], p=1.65x10 -6 ; Figure 2C ). Whilst no signals in the severity association analysis reached either the corrected p-value threshold in the replication stage or genome-wide significance threshold in the metaanalysis, eight out of the selected ten independent signals showed a concordant direction of effect between the discovery and replication stages, including the intronic KIF26B variant rs35338958. Given previous literature suggesting a mechanistic role for KIF26B in ectopic calcification 30 and in WNT signalling 31 , we next explored the role of both CASC20 and KIF26B as candidate loci in subsequent functional analyses. CASC20 and KIF26B are expressed in human bone, are induced in mammalian HO models, including in BMP2 stimulated human mesenchymal stem cells. To determine whether our lead susceptibility and severity genes are expressed in human bone tissue, we extracted total RNA from fresh frozen, surgically excised bone from patients undergoing joint replacement and confirmed expression of both CASC20 and KIF26B expression by real time quantitative polymerase chain reaction (RT-qPCR, Figure 3A ). Next, we explored whether KIF26B and CASC20 are differentially expressed in human multipotent adipose-derived stem cells (hMAD, Figure 3B ) 32 and in primary human bone marrow-derived mesenchymal stem cells (hMSCs, Figure 3C -E) in response to stimulation with BMP2 and osteogenic supplements. Runt-related transcription factor 2 (RUNX2) and the transcription factor Sp7/Osterix (OSX), markers of osteogenic differentiation, were robustly upregulated in both the hMADs and the hMSCs. We also identified an increase in percentage mineralisation per well at day 24 measured by Alizarin Red S staining. We observed variation in both magnitude and time-course of CASC20 and KIF26B expression between donors. This was also reflected in the expression of RUNX2 and OSX, although the sample size was insufficient to explore these relationships statistically.
In addition to upregulation of KIF26B and CASC20 expression and the observed mineralisation, KIF26B protein was also robustly expressed in hMSCs after osteogenic differentiation ( Figure 3F ). Previous investigators have reported that KIF26B localises to microtubules in human endothelial cells. 33 Our data confirm that KIF26B has at least a partial co-localisation with the cytoskeleton in MSCs ( Figure 3F ). In silico analysis 34 of a published RNASeq dataset in an in vivo model of ectopic bone formation using human foetal MSCs from an independent study 35 also demonstrated KIF26B induction during osteogenesis ( Figure 3G ). To study the in vivo expression of KIF26B protein following injury, we used immunohistochemistry to identify and co-localise KIF26B expression with HO formation in archived tissue from a rat tendo-Achilles scalpelinduced injury model. 36, 37 In these tissues taken at 10 weeks after injury, islands of new bone formation were identified and co-localised with KIF26B expression ( Figure 3H ).
Knockout of murine Kif26b prevents BMP2-mediated mineralisation of C2C12
myoblasts. Whilst in vitro models that precisely recapitulate the injury and pathogenesis of clinical HO are lacking, C2C12 mouse myoblasts are a commonly used proxy. 38, 39 To substantiate the functional impact of KIF26B during osteogenic transdifferentiation, C2C12 mouse myoblasts were cultured following BMP2 stimulation, leading to a robust increase in Kif26b RNA from day 8 ( Figure 4A ). Of note, Kif26b RNA was very low or completely absent in undifferentiated cells at day 0. This absence of expression was further verified at the protein level, as was its upregulation after 8 days of osteogenic differentiation. Kif26b RNA was only expressed in the presence of BMP2 plus osteogenic supplements and was not detected with either low serum media, or with osteogenic supplements alone ( Figure 4C , wild type cells).
In cells engineered with CRISPR/Cas9 to not produce KIF26B, there was no expression of Kif26b RNA with BMP2 stimulation, in contrast to that observed in the wild-type C2C12 myoblasts ( Figure 4B ). In the Kif26b CRISPR cells, mRNA expression was close to the limit of detection at all time-points studied. Western blot confirmed that no KIF26B protein was produced by the Kif26b CRISPR cells after 8 days of BMP2 stimulation ( Figure 4C ). Cells of different passage number were stimulated with BMP2
in independent experiments and lysed for western blotting (n=3), confirming the stability of the Kif26b CRISPR in the C2C12 myoblasts. C2C12 myoblasts express genes promoting osteogenesis and produce mineral when stimulated with BMP2. 38 Here, we examined the effects of Kif26b CRISPR on the ability of these cells to produce mineral in a 24-day differentiation experiment using Alizarin Red S staining at days 8 and 24 postconfluency. Figure 4D shows that very little mineral is produced by day 8 in either the WT or Kif26b CRISPR cells. By day 24, only a small amount of mineral is produced by the Kif26b CRISPR cells whilst the WT cells produce abundant mineral (3.7% vs 43.3% mean mineralisation, figure 4D-E).
Kif26b knockout disrupts the mineralisation and trans-differentiation of C2C12
myoblasts by modulating the expression of osteogenic genes. Given the lack of mineralisation in the Kif26b CRISPR cells, we hypothesised that the expression of genes driving osteogenesis would be abrogated. RT-qPCR analysis of Runx2, Osx and osteocalcin (Bglap) at day 0 (confluency), day 8, 16 and 24 was conducted to test this.
At day 0, there was no difference in target gene expression between WT and Kif6b CRISPR . The greatest differential gene expression between cell types was observed at day 8 ( Figure 4F ). Expression of Runx2 peaked at day 8 in the WT cells (WT versus Kif26b CRISPR cells, p=0.0052). Osx expression in WT cells increased relative to the Kif26b CRISPR cells at day 8, 16 and 24 (p<0.0001 at all treatment timepoints). We also found that Osteocalcin was upregulated in the WT cells but not expressed in Kif26b CRISPR cells at day 8, 16 and 24 ( Figure 4F ; p<0.0001),
KIF26B deficiency inhibits ERK MAP kinase activation during osteogenesis,
whilst augmenting p38 and SMAD 1/5/8 phosphorylation. In order to understand the molecular mechanism for the abrogated osteogenic response to BMP2 stimulation in Kif26b CRISPR cells, the activity of key BMP2-effector pathways was tested in wild type and Kif26b CRISPR cells before and after osteogenic differentiation ( Figure 5A -B).
The activation of ERK MAPK is critical to osteoblast differentiation in mouse models, 40 Runx2 and osteocalcin/Bglap being major targets of this pathway. [41] [42] [43] In line with these studies, we found that phosphorylation of ERK during osteogenesis was profoundly inhibited in the absence of KIF26B protein ( Figure 5A-B ). At the same time, phosphorylation of SMAD1/5 and p38 MAPK were not negatively affected in Kif26b CRISPR cells, suggesting that Kif26b is not a critical regulator of these signalling axes in our BMP2-driven model. Mechanistically, RUNX2 has been shown to colocalise with SMADs and form part of a transcriptional activator complex to initiate BMP2 induced osteogenesis. 44 We thus speculate that the impaired Runx2 expression seen in Kif26b CRISPR cells may be sufficient to inhibit osteogenesis. A summary of the proposed functional mechanisms for KIF26B is shown in Figure 5C .
DISCUSSION
The development of HO is a clinically important sequel of musculoskeletal injury, and for which we currently have only blunt therapeutic tools (radiotherapy or non-steroidal anti-inflammatory agents) that have significant off-target effects. Here, we conducted genome-wide association analyses for HO and identify a robustly replicating locus for HO susceptibility within the previously uncharacterised human-only LNC RNAencoding gene CASC20. We demonstrate its expression in bone and differential expression in human MSC populations in response to an osteogenic stimulus, resulting in mineralised nodule formation. We also find suggestive evidence of association between variance in the kinesin gene KIF26B and the severity of formed HO. Based upon this finding, and prior evidence of Kif26b expression in an in vitro murine model of ectopic ossification 30 and in WNT signalling, 31, 45 we demonstrate KIF26B expression in human bone and its protein in a rat model of HO; and its differential expression in human MSCs in response to an osteogenic stimulus, resulting in mineralised nodule formation. We further show that modulation of KIF26B in a murine myoblast model is sufficient to inhibit osseous trans-differentiation, an effect that is associated with ERK1/2 dysregulation. p38 MAPK has also been linked to osteogenic differentiation. However, the direction of its effect in this process remains unclear. Whilst a number of studies have shown that p38 activity is required for osteogenesis downstream of BMP2, 20, 46 it has also been reported that inhibition of this pathway can augment osteogenic differentiation. 47 A recent study showed that TNF inhibited BMP2-mediated osteogenesis via a strong activation of p38 MAPK in C2C12 and MC3T3-E1 cells whilst inhibition of p38 rescued the expression of RUNX2 and other osteogenic markers induced by BMP2. 48 Our analysis of the consequences of Kif26b-deficiency demonstrate over-activity of this pathway, which may also contribute to the observed lack of osteogenesis.
Within the power constraints of our study, we found no evidence to implicate variation within BMP2 or ACVR1, suggesting that the rare disorder FOP does not provide an aetiological cue in common, complex HO. Although both the discovery and replication sample sizes were limited, the genotyped collections studied here amass the largest available sample size globally. Larger sample sizes will be necessary to increase the number of HO risk loci robustly identified, and to discover disease severity signals ( Supplementary Figure 3 ). Further studies of the gene encoding CASC20 in relevant human cell models will help clarify the role of CASC20 in human health and disease and in the pathogenesis of HO.
We used the C2C12 myoblast cell line to model HO in vitro, as muscle precursor cells may contribute to the cellular origin of HO. 49 This is a sub-clone of a line originally derived from traumatised mouse muscle tissue. 50, 51 This immortalised cell line will readily differentiate into myotubes, adipoblasts or osteoblasts when stimulated under appropriate conditions. 34, 47 When stimulated with BMP2, this cell line is useful in the study of osteogenic differentiation and particularly in the context of HO. 18, 39, [52] [53] [54] [55] [56] [57] Whilst the mechanistic insight from this cellular model has been valuable, this approach also has limitations. It recapitulates a single cell of origin picture of acquired HO that is known to be complex and involving the interaction of multiple cell types of different embryonal lineages, and the dominant initiating cell type remains unknown.
In summary, here we provide first insights into the genetic architecture of common, complex HO, revealing a susceptibility locus within a LNC RNA encoding gene, and early mechanistic insight into BMP2 modulated signalling in its pathogenesis that may provide opportunities for further investigation as potentially actionable targets in its prevention. Discovery cohort. 891 British Caucasian men and women (481 controls and 410 cases) who had previously undergone hip replacement for idiopathic osteoarthritis were studied. 59 Controls comprised subjects who had no evidence of HO on plain AP radiographs of the pelvis taken not less than 1 year following primary THA. Cases comprised subjects with radiographic evidence of post-operative HO and were graded (0-4) using the Brooker classification. 60 Brooker described: a small island of bone (class 1); bone spurs from pelvis and proximal femur leaving at least 1cm between opposing surfaces (class 2); bone spurs from pelvis and proximal femur leaving gap less than 1cm (class 3); apparent ankylosis of the hip (class 4). The distribution of patient demographics and the presence and severity of HO by Brooker classification are shown in Supplementary Table 8 .
METHODS
Replication cohort. 419 British Caucasian subjects (207 cases and 212 controls) were recruited not less than 1 year following hip replacement for idiopathic osteoarthritis.
HO was graded from plain pelvic radiographs as outlined above using the Brooker grading. Cohort demographics and distribution of Brooker grades for the samples proceeding to case control association analyses are shown in Supplementary Table 8 .
Discovery GWAS. DNA from subjects in the discovery cohort was extracted from either whole blood or saliva and genotyped using the Illumina 610k beadchip (Illumina, San Diego, CA). Standard GWAS QC was conducted at the samples and variants level.
The exclusion criteria have been previously described. 59, 61 Briefly, individuals with 1) gender discrepancy; 2) call rate <95% (<97% in arcOGEN 61 ); 3) excess homozygosity or heterozygosity (more than ±3 SD of the mean); 4) duplicates and related samples (π^ >0.2); 5) non-UK European ancestry (ethnicity outliers) were excluded from further analyses. Variants with 1) minor allele frequency (MAF) ≥5% and a call rate <95%, or a MAF <5% and call rate <99%; 2) monomorphic; 3) exact Hardy Weinberg Equilibrium (HWE) p<0.05 (p<0.0001 in arcOGEN) were also excluded from the merged dataset. Variant QC was carried out on autosomal variants. Genotype-calling intensity plots were examined and single nucleotide polymorphisms (SNPs) with poorly clustering plots were not taken forward. Following QC, 891 subjects (481 controls and 410 cases) and 448770 variants were imputed with IMPUTE2 62 using the European reference panel from the 1000 Genomes Project (Dec 2010 phase I interim release). 63 Variants with an imputation information score <0.4 and MAF <0.05 were excluded from further analysis.
An HO susceptibility case-control analysis and an evaluation of disease severity using a binomial analysis of Brooker grades 1 and 2 versus grades 3 and 4 (within cases only) were undertaken on >10 million variants under the additive model using method score implemented in SNPTESTv2. 62 Analyses were adjusted for age and sex as they are known risk factors for HO. 64 Data were pruned for linkage disequilibrium (LD) using the clumping function in PLINK. 26 Replication and meta-analysis. DNA from the subjects in the replication cohort was extracted from saliva and genotyped using the iPLEX® Assay of the MassARRAY® System (Agena Bioscience, Inc) to conduct de novo replication. Thirty independent and prioritised variants of the discovery stage (20 susceptibility and 10 severity loci; Supplementary Table 9 ) were genotyped. All variants had high Agena design metrics and thus were not replaced with highly correlated proxies. QC was conducted at the sample and variant levels. Sample exclusions were based on sex inconsistencies and a sample call rate <60%. Variants with a call rate <75%, minor allele frequency (MAF) <1% and exact HWE P<0.001 in controls were also excluded. Following QC, 205 controls and 198 cases and 23 variants (13 susceptibility and 10 severity) proceeded to association analyses. An HO susceptibility case-control analysis and an evaluation of disease severity using a binomial analysis within cases were undertaken under the additive genetic model using the "method maximum likelihood" option as implemented in SNPTESTv2.5.2. 62 Age and sex were used as covariates. 64 The significance threshold for association in the replication study was 0.05/23=0.0022. Finally, we performed a fixed-effects inverse-variance-weighted meta-analysis in METAL 65 across the discovery and replication datasets, comprising a total of 1294 (608 cases and 686 controls) and 608 (136 severe cases and 472 mild cases) individuals for case-control and severity analyses, respectively. Genome-wide significance was defined as p<5.0 × C2C12 WT and Kif26b CRISPR cells were cultured in growth medium for 24 hours after seeding onto culture plates. Subsequently, growth medium ±BMP was added for 48 hours as for the MSC cultures, at which point the cells were a confluent monolayer.
After confluency, the media was changed to one of the three differentiation media Immunohistochemistry. Achilles tenotomy in the rat is an established model of heterotopic ossification that closely recapitulates heterotopic ossification associated with joint replacement. 36, 37, 66 
